Literature DB >> 27097276

Criminal Charges Prior to and After Enrollment in Opioid Agonist Treatment: A Comparison of Methadone Maintenance and Office-based Buprenorphine.

Darius A Rastegar1, Sarah Sharfstein Kawasaki2, Van L King3, Elizabeth E Harris4, Robert K Brooner3.   

Abstract

BACKGROUND: Entry into methadone maintenance is associated with a reduction in criminal activity; less is known about the effects of office-based buprenorphine.
OBJECTIVE: To compare criminal charges before and after enrollment in methadone maintenance or office-based buprenorphine.
METHODS: Subjects were opioid-dependent adults who initiated either methadone maintenance (n = 252) or office-based buprenorphine (n = 252) between 2003 and 2007. Medical records were reviewed to gather demographic data and a state-maintained web-based database to collect data on criminal charges. Overall charges and drug charges in the 2 years prior to and after treatment enrollment were compared. Multivariable analysis was used to examine risk factors for charges after treatment enrollment.
RESULTS: In the 2 years after enrolling in treatment, subjects receiving methadone had a significant decline in the proportion of subjects with any charges (49.6% vs. 32.5%, p < .001) or drug charges (25.0% vs. 17.5%, p = .015), as well as the mean number of cases (0.97 vs. 0.63, p = .002) and drug cases (0.38 vs. 0.23, p = .008), while those who initiated buprenorphine did not have significant changes in any of these measures. On multivariable analysis, the strongest predictor of criminal charges in the 2 years after treatment enrollment was prior charges (adjusted odds ratio 3.35, 95% confidence interval, 2.24-5.01).
CONCLUSIONS: Enrollment in office-based buprenorphine treatment did not appear to have the same beneficial effect on subsequent criminal charges as methadone maintenance. If this observation is replicated in other settings, it may have implications for matching individuals to these treatment options.

Entities:  

Keywords:  Crime; buprenorphine; methadone; opioid agonist treatment; opioid-related disorders

Mesh:

Substances:

Year:  2016        PMID: 27097276     DOI: 10.3109/10826084.2016.1155608

Source DB:  PubMed          Journal:  Subst Use Misuse        ISSN: 1082-6084            Impact factor:   2.164


  2 in total

1.  Heroin refusal self-efficacy and preference for medication-assisted treatment after inpatient detoxification.

Authors:  Shannon R Kenney; Genie L Bailey; Bradley J Anderson; Michael D Stein
Journal:  Addict Behav       Date:  2017-05-09       Impact factor: 3.913

2.  The Role of Gender in Suicidal Ideation among Long-term Opioid Users.

Authors:  Kirsten Marchand; Heather Palis; Jill Fikowski; Scott Harrison; Patricia Spittal; Martin T Schechter; Eugenia Oviedo-Joekes
Journal:  Can J Psychiatry       Date:  2017-05-18       Impact factor: 4.356

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.